Brief training can improve the effective communication of bad news to patients with cancer, according to a recently published randomized controlled trial and a separate evidence-based review.
Adherence to antiemetic regimens for patients undergoing emetogenic cancer chemotherapy is poor, according to an online survey of oncology nurses in the United States.
Adding ginger extract capsules to a standard prophylactic antiemetic did not improve chemotherapy-induced nausea and vomiting in patients undergoing high-dose cisplatin chemotherapy.
What are secondary adjuvant therapy options for stages II–IV ovarian cancer patients in complete remission? And do you know if fertility preservation is possible in patients with stage I ovarian cancer? Test your knowledge on these topics and more in our latest quiz.
Epacadostat plus pembrolizumab yielded “encouraging response outcomes” among patients with 0 or 1 prior lines of therapy for advanced renal cell carcinoma.
Germline genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will test positive for pathogenic gene variants.
In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.
Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.
Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.